Stockscreener 앱 받기
10.41
3.34%
-0.36
시간 외 거래:
10.85
0.44
+4.23%
Cervomed Inc 주식(CRVO)의 최신 뉴스
CervoMed shares coverage initiated with buy rating on DLB drug potential - Investing.com UK
CervoMed Inc. (NASDAQ:CRVO) Sees Large Growth in Short Interest - MarketBeat
CervoMed FY2024 EPS Lowered by Brookline Capital Management - MarketBeat
AWM Investment Company, Inc. Expands Stake in CervoMed Inc - GuruFocus.com
CervoMed appoints Ordonez, Rosch as SVPs - TipRanks
CervoMed bolsters leadership for neurologic drug development By Investing.com - Investing.com Nigeria
CervoMed bolsters leadership for neurologic drug development - Investing.com
CervoMed Announces Key Senior Leadership Appointments - GlobeNewswire
CervoMed Bolsters Leadership Team Ahead of Crucial Lewy Body Dementia Drug Trial | CRVO Stock News - StockTitan
CervoMed Inc. Reports Increased R&D Expenses Amid Ongoing Trials - TipRanks
CervoMed Inc. (CRVO) Quarterly 10-Q Report - Quartz
CervoMed Inc. Announces Executive Appointments - Marketscreener.com
CervoMed Reports Third Quarter 2024 Financial Results and Provides Corporate Updates - The Manila Times
CervoMed's Q3 Loss Widens to $4.8M Despite $46.7M Cash Reserve; Awaits Key Trial Data | CRVO Stock News - StockTitan
CervoMed Awarded the Prix Galien USA 2024 Prize for Best Startup - GlobeNewswire
CervoMed to Participate in Upcoming Investor Conferences - StockTitan
CervoMed Announces Key Takeaways from Oral Presentations at the 17th Clinical Trials on Alzheimer's Disease Conference (CTAD) - The Manila Times
CervoMed Announces Key Takeaways from Oral Presentations at - GlobeNewswire
CervoMed Inc. (NASDAQ:CRVO) Short Interest Up 7.6% in October - MarketBeat
CervoMed (NASDAQ:CRVO) Shares Down 3.1% – Time to Sell? - Defense World
CervoMed (NASDAQ:CRVO) Stock Price Down 3.1%What's Next? - MarketBeat
CervoMed to Present Phase 2b Trial Results - TipRanks
CervoMed to Deliver Oral Presentation at the 8th International Lewy Body Dementia Conference - GlobeNewswire
Insiders of CervoMed Inc. (NASDAQ:CRVO) were rewarded after last week’s 11% gain - Simply Wall St
CRVOCervoMed Inc. Latest Stock News & Market Updates - StockTitan
CervoMed Announces Last Patient Last Visit in Phase 2b - GlobeNewswire
CervoMed Announces Last Patient Last Visit in Phase 2b RewinD-LB Trial of Neflamapimod for the Treatment of Early-Stage Dementia with Lewy Bodies (DLB) - StockTitan
CervoMed Ends $20 Million Stock Sales Agreement with BTIG - Yahoo Finance
CervoMed ends sales agreement with BTIG By Investing.com - Investing.com South Africa
CervoMed ends sales agreement with BTIG - Investing.com India
CervoMed to Participate in 3rd Annual ROTH Healthcare Opportunities Conference - GlobeNewswire
CervoMed Inc. (NASDAQ:CRVO) Short Interest Update - MarketBeat
CervoMed to Deliver Late-Breaking Oral Presentations at the 17th Clinical Trials on Alzheimer's Disease Conference (CTAD) - The Manila Times
CervoMed to present on neflamapimod as DLB treatment at CTAD - TipRanks
CervoMed to Deliver Late-Breaking Oral Presentations at the - GlobeNewswire
Armistice Capital LLC Sells 94,363 Shares of CervoMed Inc. (NASDAQ:CRVO) - MarketBeat
There is no way Cerence Inc (CRNC) can keep these numbers up - SETE News
Credo Technology Group (NASDAQ:CRDO) Trading Up 3% - MarketBeat
Certara Inc (CERT)’s Ratio Roundup: Key Metrics for Trailing Twelve Months - The Dwinnex
Closing Figures Unveiled: Cemtrex Inc. (CETX) Drop -3.49, Closes at 0.14 - The Dwinnex
Examining Certara Inc (CERT) more closely is necessary - US Post News
Cerence Inc. (CRNC)’s $40 Million Revenue Guidance Signals Trouble for Investors - Insider Monkey
(CRVO) Technical Pivots with Risk Controls - Stock Traders Daily
CERo Therapeutics, Inc. Announces Financing and Provides Update on Investigational New Drug Application for CER-1236 - StockTitan
Holdings of CERo Therapeutics Holdings Inc. (CERO) are aligned with the stars - SETE News
CERo Therapeutics Holdings Inc. (CERO)’s Ratio Roundup: Key Metrics for Trailing Twelve Months - The Dwinnex
With 65% ownership, Cerus Corporation (NASDAQ:CERS) boasts of strong institutional backing - Yahoo Finance
Renaissance Technologies LLC Has $8.34 Million Position in Commercial Vehicle Group, Inc. (NASDAQ:CVGI) - Defense World
Croda International (OTCMKTS:COIHD) Sets New 52-Week Low at $26.75 - Defense World
Crescita Therapeutics Announces Approval of Normal Course Issuer Bid - Business Wire
A significant driver of top-line growth: Certara Inc (CERT) - SETE News
Cerence Inc’s latest rating changes from various analysts - Knox Daily
3.66%
1.11%
자본화:
|
볼륨(24시간):